Boston Scientific limits sales of new stent following reports of device problems
This article was originally published in Clinica
Executive Summary
Boston Scientific has scaled down the US launch of its newly-approved NIR coronary stent following a series of reported balloon failures during the placement of the device. The problems occurred when the stent was placed using the Ranger over-the-wire delivery system in conjunction with the SOX stent securement system.